Multicenter research of comparison between prasugrel and clopidogrel in ischemic heart disease undergoing PCI

Multicenter research of comparison between prasugrel and clopidogrel in ischemic heart disease undergoing PCI - comparison between prasugrel and clopidogrel

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029481

Enrollment

1500

Registered

2017-10-10

Start date

2017-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ischemic heart disease patinets undergoing PCI between May 2014 to May 2016 who started newly prasugrel or clopidogrel and kept dual anti-platelet therapy.

Exclusion criteria

Exclusion criteria: Prescribed P2Y12 inhibitors before first PCI more than a month ago Switching P2Y12 inhibitors within 2weeks without comprehensible reasons Self-interruption of P2Y12 inhibitors Follow-up periods within 2 weeks Not documented doses of P2Y12 inhibitors

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke. Adverse events were defined as a composite of bleeding, hepatopathy, leukopenia, thrombopenia, exanthema, and MACE.	—

Countries

Japan

Contacts

Public ContactSatoshi Tokimasa

Chiba University Graduate school of medicine Cardiovascular medicine

YFD02270@nifty.com043-222-7171

Outcome results